Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Richard F. Pops

CEORichard F. Pops

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

8.76B

Market cap8.76B

Price-Earnings ratio

61.23

Price-Earnings ratio61.23

Dividend yield

—

Dividend yield—

Average volume

3.56M

Average volume3.56M

High today

$54.45

High today$54.45

Low today

$52.23

Low today$52.23

Open price

$54.01

Open price$54.01

Volume

2.94M

Volume2.94M

52 Week high

$55.28

52 Week high$55.28

52 Week low

$25.17

52 Week low$25.17

Stock Snapshot

As of today, Alkermes(ALKS) shares are valued at $52.53. The company's market cap stands at 8.76B, with a P/E ratio of 61.23.

During the trading session on 2026-06-30, Alkermes(ALKS) shares reached a daily high of $54.45 and a low of $52.23. At a current price of $52.53, the stock is +0.6% higher than the low and still -3.5% under the high.

Trading volume for Alkermes(ALKS) stock has reached 2.94M, versus its average volume of 3.56M.

The stock's 52-week range extends from a low of $25.17 to a high of $55.28.

ALKS News

Simply Wall St 15h

Alkermes Advances Alixorexton As Valuation Debate Follows Phase 2 Narcolepsy Data

Advertisement Why the Vibrance-2 data matters for Alkermes stock Alkermes (ALKS) recently reported detailed phase 2 Vibrance-2 data for alixorexton in narcole...

TipRanks 19h

Alkermes downgraded to Underperform from Neutral at BofA

BofA analyst Jason Gerberry downgraded Alkermes (ALKS) to Underperform from Neutral with a $38 price target With shares up 92% year-to-date, the firm acknowledg...

Simply Wall St 3d

Why Alkermes Is Up 22.4% After Strong Phase 2 Narcolepsy Data For Alixorexton

Alkermes recently reported detailed positive phase 2 Vibrance-2 results for its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 2, sho...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

12.5%

Sell

6.3%

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.